HLS Therapeutics (TSE:HLS) Sets New 52-Week Low – What’s Next?

HLS Therapeutics Inc. (TSE:HLS)’s stock price reached a new 52-week low on Thursday . The stock traded as low as C$3.78 and last traded at C$3.77, with a volume of 287090 shares trading hands. The stock had previously closed at C$3.98.

Analyst Ratings Changes

Separately, Canaccord Genuity Group raised shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, HLS Therapeutics has an average rating of “Buy” and an average target price of C$6.00.

HLS Therapeutics Trading Down 2.8%

The company has a debt-to-equity ratio of 75.00, a current ratio of 1.00 and a quick ratio of 1.01. The firm has a market capitalization of C$121.03 million, a PE ratio of -12.09 and a beta of -0.18. The firm’s fifty day moving average is C$4.24 and its two-hundred day moving average is C$4.42.

HLS Therapeutics (TSE:HLS) last announced its earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share for the quarter. The business had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.During the same quarter in the previous year, the firm earned ($0.09) EPS. On average, equities analysts predict that HLS Therapeutics Inc. will post -0.12 EPS for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.